Home » Stocks » Gossamer Bio

Gossamer Bio, Inc. (GOSS)

Stock Price: $9.53 USD 0.12 (1.28%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 722.64M
Revenue (ttm) n/a
Net Income (ttm) -224.14M
Shares Out 75.83M
EPS (ttm) -3.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $9.53
Previous Close $9.41
Change ($) 0.12
Change (%) 1.28%
Day's Open 9.38
Day's Range 9.30 - 9.64
Day's Volume 390,569
52-Week Range 7.52 - 27.15

More Stats

Market Cap 722.64M
Enterprise Value 299.49M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 75.83M
Float 56.10M
EPS (basic) -3.57
EPS (diluted) -3.58
FCF / Share -2.66
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.86M
Short Ratio 9.20
Short % of Float 17.57%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.65
Revenue n/a
Operating Income -226.08M
Net Income -224.14M
Free Cash Flow -177.14M
Net Cash 423.16M
Net Cash / Share 5.58
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -22.82%
ROE -52.02%
ROIC -75.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(109.86% upside)
Current: $9.53
Target: 20.00
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-186-149-6.65-0.08
Net Income-180-147-6.77-0.08
Shares Outstanding54.746.509.169.16
Earnings Per Share-3.29-22.59-0.74-0.01
Operating Cash Flow-145-51.04-5.750.02
Capital Expenditures-2.97-3.49--
Free Cash Flow-148-54.53-5.750.02
Cash & Equivalents4022290.320.06
Total Debt37.20-6.040.04
Net Cash / Debt365229-5.730.02
Book Value352-120-6.86-0.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Gossamer Bio, Inc.
Country United States
Employees 171
CEO Sheila Gujrathi

Stock Information

Ticker Symbol GOSS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GOSS
IPO Date February 8, 2019


Gossamer Bio, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.